770 related articles for article (PubMed ID: 18338833)
1. Potent antitumor effect of TRAIL mediated by a novel adeno-associated viral vector targeting to telomerase activity for human hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Zhong S; Liu X; Tan WS
J Gene Med; 2008 May; 10(5):518-26. PubMed ID: 18338833
[TBL] [Abstract][Full Text] [Related]
2. Suppression of cancer growth in mice by adeno-associated virus vector-mediated IFN-beta expression driven by hTERT promoter.
He LF; Wang YG; Xiao T; Zhang KJ; Li GC; Gu JF; Chu L; Tang WH; Tan WS; Liu XY
Cancer Lett; 2009 Dec; 286(2):196-205. PubMed ID: 19564073
[TBL] [Abstract][Full Text] [Related]
3. [Specific antitumor effect of adeno-associated virus vector carrying TRAIL gene under the control of hTERT promoter].
Qi R; Cai Y; Li BH; Lin ZX; Gu JF
Ai Zheng; 2008 Oct; 27(10):1026-33. PubMed ID: 18851780
[TBL] [Abstract][Full Text] [Related]
4. AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice.
Zhang Y; Ma H; Zhang J; Liu S; Liu Y; Zheng D
Life Sci; 2008 Jun; 82(23-24):1154-61. PubMed ID: 18485417
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Wu Y; He G; Tan WS
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1827-37. PubMed ID: 20213096
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antitumor effect of combining interferon beta with TRAIL mediated by tumor-targeting adeno-associated virus vector on A549 lung cancer xenograft.
Wang Y; He L; He G; Kong Y; Liu X; Cai H; Liu X; Tan W
Sheng Wu Gong Cheng Xue Bao; 2010 Jun; 26(6):780-8. PubMed ID: 20815258
[TBL] [Abstract][Full Text] [Related]
7. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter.
Jacob D; Davis J; Zhu H; Zhang L; Teraishi F; Wu S; Marini FC; Fang B
Clin Cancer Res; 2004 May; 10(10):3535-41. PubMed ID: 15161713
[TBL] [Abstract][Full Text] [Related]
8. Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice.
Ma H; Liu Y; Liu S; Xu R; Zheng D
Hepatology; 2005 Dec; 42(6):1355-63. PubMed ID: 16317690
[TBL] [Abstract][Full Text] [Related]
9. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and canstatin gene suppression therapy on breast tumor xenograft growth in mice.
Wang WB; Zhou YL; Heng DF; Miao CH; Cao YL
Breast Cancer Res Treat; 2008 Jul; 110(2):283-95. PubMed ID: 17899369
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antitumoral effects of human telomerase reverse transcriptase-mediated dual-apoptosis-related gene vector delivered by orally attenuated Salmonella enterica Serovar Typhimurium in murine tumor models.
Fu W; Chu L; Han X; Liu X; Ren D
J Gene Med; 2008 Jun; 10(6):690-701. PubMed ID: 18338832
[TBL] [Abstract][Full Text] [Related]
11. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity.
Gu J; Andreeff M; Roth JA; Fang B
Gene Ther; 2002 Jan; 9(1):30-7. PubMed ID: 11850720
[TBL] [Abstract][Full Text] [Related]
12. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes.
Lin T; Gu J; Zhang L; Huang X; Stephens LC; Curley SA; Fang B
Cancer Res; 2002 Jul; 62(13):3620-5. PubMed ID: 12097263
[TBL] [Abstract][Full Text] [Related]
13. [Construction of TRAIL gene eukaryotic expression vector modulated by hTERT gene core promoter and its effect on apoptosis of ovarian cancer cells].
Li HM; Song TB; Yu YC; Cao YX; Wang HY; Song H; Zhang M
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Mar; 22(2):243-6. PubMed ID: 16507264
[TBL] [Abstract][Full Text] [Related]
14. [In vitro treatment of ovarian cancer cells with cytosine deaminase-thymidine kinase fusion disuicide gene therapy system under the control of human telomerase reverse transcriptase gene promoter].
Kong BH; Song Y; Ma DX; Qu X; Jiang S
Zhonghua Fu Chan Ke Za Zhi; 2004 Jun; 39(6):390-5. PubMed ID: 15312323
[TBL] [Abstract][Full Text] [Related]
15. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter.
Komata T; Kondo Y; Kanzawa T; Hirohata S; Koga S; Sumiyoshi H; Srinivasula SM; Barna BP; Germano IM; Takakura M; Inoue M; Alnemri ES; Shay JW; Kyo S; Kondo S
Cancer Res; 2001 Aug; 61(15):5796-802. PubMed ID: 11479218
[TBL] [Abstract][Full Text] [Related]
16. Enforced expression of a truncated form of Bax-alpha (tBax) driven by human telomerase reverse transcriptase (hTERT) promoter sensitizes tumor cells to chemotherapeutic agents or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Toyota H; Kondo S; Kyo S; Mizuguchi J
Anticancer Res; 2006; 26(1A):99-105. PubMed ID: 16475685
[TBL] [Abstract][Full Text] [Related]
17. Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model.
Yoo J; Choi S; Hwang KS; Cho WK; Jung CR; Kwon ST; Im DS
J Gene Med; 2006 Feb; 8(2):163-74. PubMed ID: 16144019
[TBL] [Abstract][Full Text] [Related]
18. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters.
Majumdar AS; Hughes DE; Lichtsteiner SP; Wang Z; Lebkowski JS; Vasserot AP
Gene Ther; 2001 Apr; 8(7):568-78. PubMed ID: 11319624
[TBL] [Abstract][Full Text] [Related]
19. AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression.
Mohr A; Henderson G; Dudus L; Herr I; Kuerschner T; Debatin KM; Weiher H; Fisher KJ; Zwacka RM
Gene Ther; 2004 Mar; 11(6):534-43. PubMed ID: 14999225
[TBL] [Abstract][Full Text] [Related]
20. FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo.
Koga S; Hirohata S; Kondo Y; Komata T; Takakura M; Inoue M; Kyo S; Kondo S
Anticancer Res; 2001; 21(3B):1937-43. PubMed ID: 11497281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
